Introduction
Gentamicin (GM) is widely used as bactericidal agent for the treatment of severe infections with gram-negative bacteria, like Pseudomonas aeruginosa. Its antibacterial activity is due to an irreversible inhibition of bacterial protein synthesis. However, clinical use of aminoglycosides, like GM, is limited by their ototoxicity and nephrotoxicity. The mechanisms behind the nephrotoxity have been extensively investigated, but how these drugs induce cellular malfunction and necrosis remains to be elucidated. Accurate localization of GM in cells and tissues can be expected to contribute to this. Previously, subcellular fractionation (27) , micropuncture techniques (24) and autoradiography using radioactivelly labeled aminoglycosides (6, 26) have been used to study the mechanisms for nephrotoxity. Additionally, immunogold labeling methods have been used for studying the subcellular distribution of aminoglycosides in proximal tubules of the nephron (1, 2, 3, 4, 20) . However, these studies have been limited to an ultrastructural analysis of proximal tubule cells.
Recently, we have succesfully developed immunocytochemical (ICC) procedures for detecting cellular uptake of other water-diffusible small drugs like daunomycin (DM) (14, 15, 22, 23) . These procedures make use of glutaraldehyde-fixed tissues, which undergo a series of pretreatments to unmask sites of accumulation of the drug.
We now report on the development of an ICC method for uptake of GM in kidneys of rats injected with the drug. Importantly, we found that systematic variation of the pretreatment conditions were necessary to fully detect uptake of the drug in different cellular compartments. The new information, obtained by this method, is that GM not only accumulates in the cytoplasmic granules of the S1 and S2 segments but also in the S3 segment of the proximal tubules. Moreover, we also detected accumulation of GM in nuclei and cytoplasm of cells in the distal tubules and collecting ducts. These results indicate the importance of varying tissue pretreatment conditions when studying the distribution of small drugs which may be masked in different ways in different subcellular compartments and suggests that this approach is useful for detecting sites of uptake and potential toxicity of GM. according to our recent method using GA as a cross-linker (14) . In short, HSA (10 mg) in 1.0 ml of 1M sodium acetate and 1.0 ml of 3 mM GA were mixed and incubated at room temperature for 30 s with stirring, and to the mixture was then added GM (1 mg) in 1.0 ml of 1M sodium acetate. This was followed by incubation for 30 min before 10 mg NaBH 4 was added to terminate the reaction. The reaction mixture was furthermore incubated for 30 min, and was dialyzed against 10 mM Tris-HCl buffer, pH 7.2 for 6 hrs at 4°C.
ELISA method: This was performed similarly to our previous method for anti-spermine mAbs (13) . Wells in microtiter plates were coated either with the GM-GMBS-BSA conjugate (10 µg/ml) or GM-GA-HSA conjugate (10 µg/ml), and then incubated overnight at 4 °C with dilutions of anti-GM serum, followed by goat anti-rabbit IgG labeled with HRP (diluted 1:2,000) for 1 h at 25°C. The amount of enzyme conjugate bound to each well was measured using o-phenylenediamine as a substrate, and the absorbance at 492 nm was read with an automatic ELISA analyzer (ImmunoMini NJ-2300, Nalje Nunc Int. Co. Ltd., Tokyo, Japan). 
Antibody dilution
Anti-GM serum produced against GMBS-conjugated GM (GM-GMBS-BSA conjugate)
was characterized by an ELISA system employing either GMBS-conjugated GM or GA-conjugated GM (GM-GA-HSA conjugate) as the solid phase antigen. As shown in Fig. 1 the GM antiserum bound almost equally well to both conjugates. This was promising because GA can be used for fixing GM in cells and tissues prior to immunocytochemistry. ELISA also showed that the antiserum reacted with unconjugated GM. However, it showed only low binding to the conjugating protein (BSA) (Fig. 1) .
Antibody specificity by ELISA inhibition test
This test was done using an ELISA system with GM-GA-HSA conjugate as an antigen.
The principle was competition between GM or analog antibiotics (streptomycin, kanamycin, amikacin and tobramycin) (free in solution), and a fixed amount of GM coated on ELISA plates. Calibration curves were plotted showing the relationship between the concentrations of the analytes and the percentage of bound anti-GA antibody, giving dose-dependent inhibition curves with GM in the range between 1 µM and 70 µM (Fig. 2) . The dose required for 50% inhibition of binding (EC50) was 7 µM with GM. No inhibition occurred with any of the GM analogs (Fig. 2) nor with the non-related antibiotics, pepleomycin, mitomycin C, and actinomycin D even at concentrations up to 1 mM (data not shown).
Immunocytochemistry (ICC)
We have recently developed an ICC procedure for the anti-cancer drug daunomycin (14, 15, 22, 23) , which requires a series of pretreatments prior to the ICC reaction. The same pretreatment conditions were tested and slightly modified for ICC detection of GM. Animals injected with GM were first perfusion-fixed with GA, followed by immersionfixation overnight at 4°C. Subsequently, sections were oxidized with 6%
hydrogen peroxide for 30 min to enhance immunostaining intensity ( 
GM uptake in rat kidney
Virtually the same pattern of uptake of GM in the kidney was observed at all time-points studied in rats injected with either 4 or 16 mg/kg of GM. However, the intensity of staining was higher in rats injected with the higher dose. Kidney sections from rats 12 h postinjection that had been digested with 0.04% protease for 15 min at 30 °C showed strong immunostaining for GM in the nuclei and cytoplasm of cells of the distal tubules (Fig. 3a) whilst weak staining occurred in cells of the collecting ducts and in cells of the thick portion of Henle's loop (Fig. 3d) . Part of the distal tubule cells and collecting duct cells were heavily stained for GM whilst others were virtually unstained, indicating a very heterogenous uptake of GM (Fig. 3a) . In both the distal tubules and collecting ducts some of the heavily stained cells were swollen and possessed large nuclei (Fig. 3a) . Surprisingly, in contrast to previous results (1, 2, 3, 4, 20), only very weak or no staining was observed in cells of the proximal tubules (Fig.   3a) . However, when the protease digestion was prolonged to 2h, strong immunostaining appeared in the S1 and S2 (the straight proximal segments located in the cortex) portions of the proximal tubules, whereas staining of the distal tubules and the collecting ducts was strongly diminished (Fig. 4) . Staining of the proximal tubule cells was confined to cytoplasmic granules of irregular shape (Fig. 3b,c) , Very weak staining was also present in the S3 (the medullary straight segments) (Figs. 3b, 4 ). In addition, the best immunostaining of the collecting duct cells was obtained by the ICC with a 30-min protease digestion of the kidney specimens (Fig. 3d) The glomeruli, thin portions of Henle's loop, and endothelial cells were virtually unstained under all protease digestion conditions tested (Fig. 3b) . Similar results were observed in rats 24
and 48 h after GM injection. In control rats, receiving saline instead of GM, no staining was detected (Fig. 3g) . Conventional immunocytochemical staining controls (second level controls) were all negative (data not shown) and absorption controls using the on June 16, 2017 by guest http://aac.asm.org/ Downloaded from GM-GA-BSA conjugate at 10 µg/ml abolished all staining (Fig. 3h ).
Additionally we examined rats sacrificed 1 h after injection of GM. The relationship between the protease digestion, and the sites and intensity of immunoreaction for GM in the kidney was almost the same as in the specimens 12 h after injection (Fig. 3f) .
However, 1 h postinjection, the microvilli of the proximal tubule cells were strongly immunostained following a 15-to 60-min protease predigestion (Fig. 3e ) but were unstained when digestion was prolonged to 2 h (Fig. 3f) . Anti-GM serum was produced against a GM-GMBS-BSA conjugate and tested for reactivity towards both GMBS-conjugated GM and GA-conjugated GM. The antiserum bound almost equally well to both conjugates, indicating that it recognized the GM molecule rather than the conjugation site(s) of GMBS with GM. The anti-GM serum reacted with GM, but not with a number of related and unrelated antibiotics. The fact that it recognized GM conjugated to HSA with GA suggested that it could be useful for immunocytochemical studies of GM uptake in GA-fixed tissues. In agreement with our previous experiences with small water-soluble antigens animals injected with the drug were perfusion-fixed with GA in order to immobilize the antigen in the tissue as rapidly as possible.
Following systematic testing of several pretreatments aiming at demasking GM immunoreactivity in fixed tissues and for reducing background staining we succeeded in specifically localizing GM in kidneys of rats injected with the drug. Interestingly, optimal conditions for immunostaining with respect to the protease digestion varied in the respective segments of the nephron. These differences may reflect differences in binding and masking of GM by proteins and other macromolecules in different cellular compartments, and may thus constitute different obstacles for antibody to penetrate into such segments. Accordingly, to reveal the full complement of GM localization, results from different digestion procedure needed to be evaluated. (28), could localize uptake of GM also to the S3 segments of the proximal tubules.
Furthermore, a new finding of the present study was that swollen, necrotic-like cells of the distal tubules and collecting ducts were heavily immunostained for GM.
Previously, autoradiographic studies also demonstrated the transport of aminoglycosides in the distal tubule and collecting duct as well as in the proximal tubule (6, 16, 19, 26) .
However, they have not described such swollen, necrotic-like cells. These results may suggest the possibility that GM nephrotoxicity is not restricted to the proximal tubules, but extends to the distal tubules and collecting ducts. This agrees with the report by Our data are the first to indicate the swollen, necrotic-like cells caused by the action of GM in the distal tubules.
In conclusion, our study clearly demonstrates that the anti-GM serum produced against GMBS-conjugated GM was useful for developing a GM ICC method. This method revealed that GM accumulated in the proximal and distal tubules as well as collecting ducts pinpointing all of these sites as potential targets for GM toxicity. 
